



Improving Awareness & Patient Outcomes

Kidney Disease in Asian American and Pacific Islanders

May 23, 2024

March 2024 US.CORP.D.24.00013

© 2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.

The information provided by NephU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU's educational resources. Users seeking medical advice should consult with a health care professional.



Improving Awareness & Patient Outcomes

**This program is paid for by
Otsuka Pharmaceutical Development &
Commercialization, Inc.**


**Speakers are employees and/or paid consultants of
Otsuka Pharmaceutical Development &
Commercialization, Inc.**

March 2024 US.CORP.D.24.00013

NephU Webinar Rules of Engagement

- NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI),— committed supporters of the kidney health community. Editorial development and support for NephU is provided by OPDC and OPEN MINDS, who have been compensated for their services.
- NephU is a free community and online resource library for kidney disease and other related conditions. One of the methods employed for the sharing of information will be the hosting of webinars. Webinars conducted by OPDC are based on the following parameters:
- When conducting medical dialogue, whether by presentation or debate, OPDC and/or its paid consultants aim to provide the viewer with information that is accurate, not misleading, scientifically rigorous, and does not promote OPDC products.
- No continuing medical education (CME) credits are available for any NephU program.
- OPDC and/or their paid consultants do not expect to be able to answer every question or comment during a NephU webinar; however, they will do their best to address important topics and themes that arise.
- OPDC and/or their paid consultants are not able to provide clinical advice or answer questions relating to specific patient's condition.
- Otsuka employees and contractors should not participate in this program (e.g., submit questions or comments) unless they have received express approval to do so from Otsuka Legal Affairs.
- OPDC operate in a highly regulated and scrutinized industry. Therefore, we may not be able to discuss every issue or topic that you are interested in, but we will do our best to communicate openly and directly. The lack of response to certain questions or comments should not be taken as an agreement with the view posed or an admission of any kind.

Presenters



Naoka Murakami, MD, PhD

Assistant Professor of Medicine at
Harvard Medical School and Transplant
Nephrologist at Brigham and Women's
Hospital



Kelly Chen NP-BC

Nurse Practitioner at Stanford Health Care, Medical
& Scientific Advisory Board Member and Asian
American Engagement Director at the IgA
Nephropathy Foundation, IgA Nephropathy Patient

Moderators



Alf Carroll, MS, PA-C
Nephrology Senior Medical Science Liaison
Otsuka Pharmaceutical Development and
Commercialization, Inc.



Jessica Kanai, PharmD
Nephrology Medical Science Liaison
Otsuka Pharmaceutical Development and
Commercialization, Inc.

Kidney Disease in Asian American & Pacific Islanders



- More than 24 million individuals of Asian descent live in the US¹
- Asian American population has increased significantly over the last decade¹

Population & Percent Change In US, 2010–2020¹

■ 2010 ■ 2020 M = millions

35.5% change



Asian **Alone**

55.5% change



Asian **In Combination**

38.6% change



Asian **Alone Or In Combination**

27.8% change



Native Hawaiian Or Pacific
Islander (NHPI) **Alone**

30.8% change



NHPI **In Combination**

29.5% change



NHPI **Alone Or In Combination**

1. Asian American and Pacific Islander Heritage month: May 2022. Census.gov. <https://www.census.gov/newsroom/facts-for-features/2022/asian-american-pacific-islander.html>. Published April 25, 2023. Accessed November 29, 2023.

Prevalence Of CKD & Comorbidities In Asian American & Pacific Islanders

Diabetes Incidence



Incidence of diabetes in Hawaii and California is **higher** for Asian Americans when compared to white patients¹

Diabetes & Kidney Failure



Diabetes is the **#1 cause** of kidney failure¹

Rates Of Kidney Failure



Rates of kidney failure secondary to diabetes among Asian Americans ages 30-39 doubled between 2000-2010²

Health Care Access



17% of Asian American and Pacific Islanders are **uninsured**, limiting detection of hypertension and diabetes, and possibly contributing to the risk of developing kidney disease¹


Kidney Disease-Related Mortality




Kidney disease related mortality is **higher** for individuals of Asian descent compared to white patients³

1. Race/ethnicity – kidney disease risk factors. American Kidney Fund. <https://www.kidneyfund.org/all-about-kidneys/risk-factors/raceethnicity-kidney-disease-risk-factors> Updated August 7, 2023. Accessed November 28, 2023.
2. Race, ethnicity, & kidney disease. National Kidney Foundation. <https://www.kidney.org/atoz/content/minorities-KD> Published January 13, 2023. Accessed November 28, 2023.
3. Claudel SE, et al. Kidney Medicine. 2023;5(8):100676.

Proportional Mortality From Kidney Disease By Race/Ethnicity¹



1. Claudel SE, et al. Kidney Medicine. 2023;5(8):100676.



IgA Nephropathy (IgAN) In Patients Of Asian Descent

Highest IgAN Prevalence



The highest prevalence of IgAN is seen in individuals of East Asian descent¹

Screenings & Biopsies



Prevalence could be partially attributed to increased urine screening and renal biopsies in East Asia¹

Varying Characteristics



Clinical symptoms, disease progression, and long-term outcomes may vary by ethnicity²

Progression To Kidney Failure




Patients with IgAN and Pacific Asian ancestry are at higher risk of progression to kidney failure compared to those from other parts of the globe³

Country	Cases Per Million Population (%)
CHINA	54.3
SINGAPORE	43.2
ITALY	35.2
AUSTRALIA	34.1
CZECH REPUBLIC	34.1
UNITED KINGDOM	33.9
JAPAN	31.0
FRANCE	30.2
KOREA	28.3
UNITED STATES	27.3
BRAZIL	20.1
MOROCCO	12.0


1. Suzuki Y, et al. Kidney360. 2021;2(8):1339-1348.
2. Yeo SC, et al. Nephrology. 2019;24(9):885-895.
3. Barbour SJ, et al. Kidney International. 2013;84(5):1017-1024.

Kidney Transplantation in Asian American & Pacific Islanders

- Racial and ethnic disparities in Living Donor Kidney Transplantation (LDKT) continue in the US, despite efforts to reduce disparities¹
- Asian patients have lower rates of LDKT at 2 years after being placed on the wait list compared to white patients¹



Temporal Trends In Living Donor Kidney Transplantation (LDKT) By Candidate Race/Ethnicity¹



1. Purnell TS, et al. JAMA. 2018;319(1):49-61.

Like What You Learned Today? See What's Up Next!



NephU.org/events

The NephU Community
Grows Stronger When
You're Engaged.

Follow Us
@NephUCommunity










Thanks For Attending!

Don't Forget To **Download Your Certificate Of Completion** On NephU.org Under Your **Account** Within The **Accomplishments** Section




Manage Your Account

-  Profile
-  Email Preferences
-  Event Registrations
-  Reset Password
-  Bookmarks
-  Accomplishments
-  Log Out



Download The NephU Mobile App Today!

All of Your Resources In **One** Spot



- ✓ Videos
- ✓ On-Demand Webinars
- ✓ Podcasts
- ✓ Infographics
- ✓ Kidney-Healthy Recipes

Download the **NephU App**
from Google Play or from the
Apple App Store!



NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) – committed supporters of the Kidney Health Community. The opinions expressed by NephU contributors are their own and are not endorsed or recommended by NephU or its sponsors. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgment when reviewing NephU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants for OPDC and/or OAPI.

www.nephu.org



Improving Awareness & Patient Outcomes

Kidney Disease in Asian American and Pacific Islanders

May 23, 2024

March 2024 US.CORP.D.24.00013

© 2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.

The information provided by NephU is intended for your educational benefit only. It is not intended as, nor is it a substitute for medical care or advice or professional diagnosis. Health care professionals should use their independent judgement when reviewing NephU's educational resources. Users seeking medical advice should consult with a health care professional.